Blueprint Medicines Stock Target Price and Analyst Consensus
| BPMC Stock | USD 114.05 0.27 0.24% |
The current analyst and expert consensus on Blueprint Medicines is Strong Buy with 5 hold recommendations. The current projected Blueprint Medicines target price consensus is 125.58 with 20 analyst opinions. One of the most common ways Blueprint Medicines Corp analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Some experts can also talk to Blueprint Medicines vendors, executives, and/or customers. Blueprint Medicines recommendation module provides expert sentiment on the projected Blueprint Medicines Corp target price to derive its highest and lowest estimates based on target price standard deviation of 3.3712.
Lowest Forecast 114.28 | Highest Forecast 139.39 | Target Price 125.58 |
Blueprint |
It's important to approach Blueprint Medicines' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Blueprint Medicines Target Price Consensus
Blueprint target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Blueprint Medicines' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 20 | Strong Buy |
Most Blueprint analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Blueprint stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Blueprint Medicines Corp, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBlueprint Medicines Target Price Projection
Blueprint Medicines' current and average target prices are 114.05 and 125.58, respectively. The current price of Blueprint Medicines is the price at which Blueprint Medicines Corp is currently trading. On the other hand, Blueprint Medicines' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Blueprint Medicines Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Blueprint Medicines Target Price
Blueprint Medicines Analyst Ratings
Blueprint Medicines' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Blueprint Medicines stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Blueprint Medicines' financials, market performance, and future outlook by experienced professionals. Blueprint Medicines' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Blueprint Medicines price targets
Blueprint Medicines' stock target price is an estimate of its future price, usually made by analysts. Using Blueprint Medicines' target price to determine if it is a suitable investment can be done through the following steps:- Look at Blueprint Medicines' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Blueprint Medicines' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Blueprint Medicines Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Blueprint Medicines is a key component of Blueprint Medicines valuation and have some predictive power on the future returns of a Blueprint Medicines.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Investor Favorites Invested over 300 shares | |
 | Driverless Cars Invested over 50 shares | |
 | Hedge Favorites Invested over 100 shares | |
 | Social Domain Invested few shares | |
 | Banking Invested over 30 shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Automobiles and Trucks Invested over 300 shares | |
 | Macroaxis Index Invested few shares | |
 | Momentum Invested over 50 shares | |
 | Manufacturing Invested over 30 shares | |
Check out Macroaxis Advice on Blueprint Medicines to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Please note, the presentation of Blueprint Medicines' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Blueprint Medicines' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Blueprint Medicines' management manipulating its earnings.